Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.38 |
| ▸ | FEN1 | P39748 | 6/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007134 | 1.00 | NR3C1 (0.50) | NR3C1PGRTRPV4ALOX5APFEN1 | |
| SCHEMBL2010238 | 0.86 | NR3C1 (0.46) | NR3C1PGRALOX5APFEN1METAP2 | |
| SCHEMBL2010243 | 0.86 | NR3C1 (0.46) | NR3C1PGRALOX5APFEN1METAP2 | |
| SCHEMBL2012132 | 0.79 | LMNA (0.41) | HPGDNPY1RNPY2RNPSR1LMNA | |
| SCHEMBL2012134 | 0.79 | LMNA (0.41) | HPGDNPY1RNPY2RNPSR1LMNA | |
| SCHEMBL5239044 | 0.78 | NR3C1 (0.54) | NR3C1PGRTRPV4ALOX5APFEN1 | |
| SCHEMBL2008608 | 0.78 | NR3C1 (0.54) | NR3C1PGRTRPV4ALOX5APFEN1 | |
| SCHEMBL2895681 | 0.73 | LMNA (0.47) | HPGDLMNA | |
| SCHEMBL2006367 | 0.72 | TNF (0.38) | NR3C1HPGDNPY1RNPY2RNPSR1 | |
| SCHEMBL698986 | 0.70 | ALDH1A1 (0.48) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 131/4885TRPV4 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.